Triple-Drug attack shows promise against tough blood cancer
Disease control
Recruiting now
This study tests a combination of three drugs (acalabrutinib, venetoclax, and obinutuzumab) for people with mantle cell lymphoma that has come back or not responded to treatment, as well as for those who haven't been treated yet. The goal is to find the best dose and see how many…
Phase: PHASE1, PHASE2 • Sponsor: Austin I Kim • Aim: Disease control
Last updated May 17, 2026 04:29 UTC